Cardiotoxicity Associated With Chimeric Antigen Receptor (CAR)-T Cell Therapy for Hematologic Malignancies: A Systematic Review

Hanna, Kerollos S; Kaur, Harkirat; Alazzeh, Mohammad S; Thandavaram, Abhay; Channar, Aneeta; Purohit, Ansh; Shrestha, Bijay; Patel, Deepkumar; Shah, Hriday; Mohammed, Lubna

doi:10.7759/cureus.28162

Cited by 4 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, CAR-T therapy has been associated with cardiotoxic adverse effects, especially in populations with preexisting risk factors, like prior cardiac history and dyslipidemia, among others [27]. The most common adverse effects are mediated by cytokine release syndrome and are arrhythmias, heart failure, and sudden cardiac arrest [28]. Understanding that Hispanic patients have relatively poorer access to various treatment options for NHL is critical in explaining the lower odds ratio of various MACCEs, including AMI and AF.…”

Section: Discussionmentioning

confidence: 99%

Racial Disparities in Cardiovascular and Cerebrovascular Adverse Events in Patients with Non-Hodgkin Lymphoma: A Nationwide Analysis

Uttam Chandani,

Agrawal,

Raval

et al. 2024

Medicina

View full text Add to dashboard Cite

Background and Objectives: Non-Hodgkin lymphoma (NHL) has the sixth-highest malignancy-related mortality in the United States (US). However, inequalities exist in access to advanced care in specific patient populations. We aim to study the racial disparities in major adverse cardiovascular and cerebrovascular events (MACCEs) in NHL patients. Materials and Methods: Using ICD-10 codes, patients with NHL were identified from the US National Inpatient Sample 2016–2019 database. Baseline characteristics, comorbidities, and MACCE outcomes were studied, and results were stratified based on the patient’s race. Results: Of the 777,740 patients with a diagnosis of NHL, 74.22% (577,215) were White, 9.15% (71,180) were Black, 9.39% (73,000) were Hispanic, 3.33% (25,935) were Asian/Pacific Islander, 0.36% (2855) were Native American, and 3.54% (27,555) belonged to other races. When compared to White patients, all-cause mortality (ACM) was significantly higher in Black patients (aOR 1.27, 95% CI 1.17–1.38, p < 0.001) and in Asian/Pacific Islander patients (aOR 1.27, 95% CI 1.12–1.45, p < 0.001). Sudden cardiac death was found to have a higher aOR in all racial sub-groups as compared to White patients; however, it was statistically significant in Black patients only (aOR 1.81, 95% CI 1.52–2.16, p < 0.001). Atrial fibrillation (AF) risk was significantly lower in patients who were Black, Hispanic, and of other races compared to White patients. Acute myocardial infarction (AMI) was noted to have a statistically significantly lower aOR in Black patients (0.70, 95% CI 0.60–0.81, p < 0.001), Hispanic patients (0.69, 95% CI 0.59–0.80, p < 0.001), and patients of other races (0.57, 95% CI 0.43–0.75, p < 0.001) as compared to White patients. Conclusions: Racial disparities are found in MACCEs among NHL patients, which is likely multifactorial, highlighting the need for healthcare strategies stratified by race to mitigate the increased risk of MACCEs. Further research involving possible epigenomic influences and social determinants of health contributing to poorer outcomes in Black and Asian/Pacific Islander patients with NHL is imperative.

show abstract

Section: Discussionmentioning

confidence: 99%

Racial Disparities in Cardiovascular and Cerebrovascular Adverse Events in Patients with Non-Hodgkin Lymphoma: A Nationwide Analysis

Uttam Chandani,

Agrawal,

Raval

et al. 2024

Medicina

View full text Add to dashboard Cite

show abstract

“…Cardiovascular toxicity is not uncommon in patients receiving CAR-T cells therapy (52). Adam Goldman et al (47) found that the occurrence of tachyarrhythmia was a major adverse effect of the heart.…”

Section: Cardiovascular Toxicitiesmentioning

confidence: 99%

“…Cardiovascular toxicity is not uncommon in patients receiving CAR-T cells therapy ( 52 ). Adam Goldman et al.…”

Section: Clinical Presentation Of Saes Associated With Car-t Cells Th...mentioning

confidence: 99%

Serious adverse events and coping strategies of CAR-T cells in the treatment of malignant tumors

2022

View full text Add to dashboard Cite

Chimeric antigen receptor T (CAR-T) cells technology has been successfully used in the treatment of B cell-derived hematological tumors and multiple myeloma. CAR-T cells are also being studied in a variety of solid tumors. Current clinical reports on CAR-T cells in the treatment of malignant tumors are abundant. The tumor-killing activity of CAR-T cells and the unique adverse effects of CAR-T cells have been confirmed by many studies. There is evidence that serious adverse events can be life-threatening. CAR-T cells therapy is increasingly used in clinical settings, so it is important to pay attention to its serious adverse events. In this review, we summarized the serious adverse events of CAR-T cells in the treatment of malignant tumors by reading literature and searching relevant clinical studies, and discussed the management and treatment of serious adverse events in an effort to provide theoretical support for clinicians who deal with such patients.

show abstract

Feasibility of CD19 CAR T-cell therapy in patients with cardiac lymphoma

Kuipers,

Spanjaart,

Bonifazi

et al. 2023

Leukemia & Lymphoma

View full text Add to dashboard Cite

Cardiotoxicity Associated With Chimeric Antigen Receptor (CAR)-T Cell Therapy for Hematologic Malignancies: A Systematic Review

Cited by 4 publications

References 29 publications

Racial Disparities in Cardiovascular and Cerebrovascular Adverse Events in Patients with Non-Hodgkin Lymphoma: A Nationwide Analysis

Racial Disparities in Cardiovascular and Cerebrovascular Adverse Events in Patients with Non-Hodgkin Lymphoma: A Nationwide Analysis

Serious adverse events and coping strategies of CAR-T cells in the treatment of malignant tumors

Feasibility of CD19 CAR T-cell therapy in patients with cardiac lymphoma

Contact Info

Product

Resources

About